Cost and Quality of Life in Thoracic Surgery

Abstract

Background: A critical look at the effectiveness of medical procedures and therapies is important with the increasing limitations on resources in health care. Method: The costs for treatment and the quality of life according to the SF-36 were analyzed in a retrospective health economic study on 65 patients who had undergone surgery for primary non-small-cell lung cancer. Results: The mean cost for all patients was € 7,169 per patient. 38.8 % resulted from surgery, 31.6 % were attached to the preoperative phase on the general ward, 11 % postoperatively to the general ward. Intensive care costs accounted for 18.7 %. The cost of each surgical procedure ranged from € 4,634 for a pneumonectomy to € 8,366 for a lobectomy with sleeve resection of the bronchus. The most expensive factors were staff, disposable materials, pathological investigations, and radiology services. There was no difference in these proportions with stage of tumor or the surgical procedures undertaken. Quality of life as assessed by the SF-36 questionnaire ranged from 31.82 (physical functioning) to 75.0 (social functioning) one year after the operation. These scores were lower than for those with other chronic diseases. On average, 4.62 quality-adjusted life years were achieved. The cost per QALY was € 1,970. The extent of resection and the tumor staging correlates significantly with the mean cost per QALY. Conclusion: Thoracic surgery is cost intensive. With increasing staging of the tumor, the cost for treatment increased as with increased operation complexity.

Key words

Thoracic surgery - health economic analysis - non-small-cell lung cancer - quality-adjusted life years (QALYs) - medical outcomes study short form 36 (SF-36) - quality of life

References

• 1 Weissflog D, Matthys H, Hasse J, Virchow Jr J C. Epidemiology and costs of cancer in Germany.  Pneumology. 2001;  55 (7) 333-338
• 2 Desch C E, Hillner B E, Smith T J. Economic considerations in the care of lung cancer patients.  Curr Opin Oncol. 1996;  8 126-132
• 3 Sobin L H, Wittekind C. TMN classification of malignant tumors. 5th edn. John Wiley & Sons, New York 1997
• 4 Deutsche Krankenhausgesellschaft .DKG-NT Band I, Tarif der Deutschen Rrankenhausgesellschaft (1997),. Stuttgart, Berlin, Köln; Kohlhammer 1997
• 5 Bullinger M. Erfassung der gesundheitsbezogenen Lebensqualität mit dem SF 36. Rehabilitation Georg Thieme Verlag Stuttgart, New York; 1996 35: XVII-XXX
• 6 Brazier J, Roberts J, Deverill M. The estimation of a preference based measure of health from the SF-36, J.  Health Econ.. 2002;  21 271-292
• 7 Mountain C F. Revisions in the international System for Staging lung cancer.  Chest. 1997;  111 1710-1717
• 8 Beck J R, Kassirer J P, Pauker S G. A Convenient Approximation of Life Expectancy. Am J.  Med.. 1982;  73 883-888
• 9 Statistisches Bundesamt Abgekürzte Sterbetafel für Deutschland 1997/1999. In Fachserie 1 Bevölkerung und Erwerbstätigkeit. Stuttgart; Metzger-Pöschel 2000: pp. 41-42
• 10 Nakajima J, Takamoto S, Kohono Y, Ohtsuka T. Costs of Videothoracoscopic surgery versus open resection for patients with lung carcinoma.  Cancer. 2000;  89 2497-2501
• 11 Lee S C, Tseng H Y, Wang K Y, Lee L C. Effect of a clinical pathway on selected clinical outcomes of pulmonary lobectomy.  Zhonghua Yi Xue Za Zhi. 2002;  65 (1) 7-12
• 12 Sugi K, Kaneda Y, Nawata K, Fujita N, Ueda K, Nawata S, Esato K. Cost analysis for thoracoscopy: thoracoscopic wedge resection and lobectomy.  Surg Today. 1998;  28 (1) 41-45
• 13 Lang G, Kolb C, Liewald F, Sunder-Plassmann L, Förster R. How expensive is thoracic surgery?.  Chirurg. 2002;  70 74-78
• 14 Lanuza D M, Lefaiver C, McCabe M :. Prospective study of functional status and quality of life before and after lung transplantation.  Chest. 2000;  118 115-122
• 15 Trippoli S, Vaiani M, Lucioni C, Messori A. Quality of life and utility in patients with non-small cell lung cancer. Quality-of-life Study Group of the Master 2 Project in Pharmacoecomics.  Pharmacoeconomics. 2001;  19 (8) 855-863
• 16 Handy J R, Asaph J W, Skokan L, Reed C E, Koh S, Brooks G, Douville E C, Tsen A C, Ott G Y, Silvestri G A. What happens to patients undergoing lung cancer surgery? Outcomes and quality of life before and after surgery.  Chest. 2002;  122 (1) 21-30
• 17 Zieren H U, Muller J M, Hamberger U. et al . Quality of life after surgical therapy of bronchogenic carcinoma.  Eur J Cardiothorac Surg. 1996;  10 233-237
• 18 Wright C D, Wain J C, Grillo H C, Moncure A C, Macaluso S M, Mathisen D J. Pulmonary lobectomy patient care pathway: a model to the control cost and maintain quality.  Ann Thorac Surg. 1997;  64 (2) 299-302
• 19 Welcker K, Lederle J, Schorr M, Siebeck M. Surgery and adjuvant therapy in patients with diffuse peritonitis: cost analysis.  World J Surg. 2002;  26 307-313
• 20 Leftakis A, Geitona M. Cost analysis and estimation of thoracic surgical patients with lung cancer in Greece: the case of Sotiria ICU.  Intensive Crit Care Nurs. 2001;  17 (6) 322-330